会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES
    • 新型磷酸酯基PMEA及其类似物的研究进展
    • WO2004037161A2
    • 2004-05-06
    • PCT/US2003/014821
    • 2003-05-12
    • METABASIS THERAPEUTICS, INC.REDDY, K. RajaERION, Mark D.MATELICH, Michael C.KOPCHO, Joseph J.
    • REDDY, K. RajaERION, Mark D.MATELICH, Michael C.KOPCHO, Joseph J.
    • A61K
    • C07F9/65742C07F9/65616
    • Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: Formula 1wherein:M and V are cis to one another and MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxy propyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine;V is selected from a group consisting of phenyl, 2-pyridyl , 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, C1-C3 alkyl, CF3 and OR6;R6 is selected from the group consisting of C1-C3 alkyl, and CF3;and pharmaceutically acceptable salts thereof.
    • 描述了式I的前药,其用途,其中间体及其制备方法:式1其中M和V彼此是顺式的,MPO3H2是选自9-(2-膦酰基甲氧基乙基)腺嘌呤 ,(R)-9-(2-膦酰基甲氧基丙基)腺嘌呤,9-(2-膦酰基甲氧基乙基)鸟嘌呤,9-(2-膦酰基甲氧基乙氧基)腺嘌呤,9-(2-膦酰基甲氧基乙基)-2,6-二氨基嘌呤,(S ) - (3-羟基-2-膦酰基甲氧基丙基)胞嘧啶,(S)-9-(3-羟基-2-膦酰基甲氧基丙基)腺嘌呤,9-(3-羟基-2-膦酰基甲氧基丙基)鸟嘌呤和(S) - 9-(3-氟-2-膦酰基甲氧基丙基)腺嘌呤; V选自苯基,2-吡啶基,3-吡啶基,4-吡啶基,2-呋喃基,3-呋喃基,2-噻吩基和3 噻吩基,全部任选被1-3个选自F,Cl,Br,C 1 -C 3烷基,CF 3和OR 6的取代基取代; R 6选自C 1 -C 3烷基和CF 3;和药学上 其可接受的盐。